NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cytori Therapeutics, Inc. (NASDAQ: CYTX - News) and Cord Blood America, Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at: http://www.paragonreport.com/CYTX http://www.paragonreport.com/CBAI Shares of Cytori Therapeutics have skyrocketed nearly 70 percent year-to-date. The company develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company's technology is the Celuion family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care. In late January, Cytori received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the "ATHENA" trial. ATHENA will investigate the use of the Celution System to treat a form of coronary heart disease, chronic myocardial ischemia (CMI). The Paragon Report provides investors with an excellent first step … Continue reading →

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTC.BB: ACTC.OB - News) and StemCells Inc. (NASDAQ: STEM - News). Access to the full company reports can be found at: http://www.paragonreport.com/ACTC http://www.paragonreport.com/STEM Shares of StemCells Inc. have skyrocketed nearly 20 percent year-to-date. StemCells Inc. is focused on cellular medicine, or the use of stem and progenitor cells as the basis for therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. Earlier this month the company released a statement saying that it received U.S. Food and Drug Administration authorization to start a clinical trial of the company's potential treatment for dry age-related macular degeneration, or AMD. AMD is the leading cause of vision loss and blindness … Continue reading →

Public release date: 14-Feb-2012 [ | E-mail | Share ] Contact: Jennifer Beal healthnews@wiley.com 44-124-377-0633 Wiley-Blackwell Stem cell therapy moderately improves heart function after a heart attack, according to a systematic review published in The Cochrane Library. But the researchers behind the review say larger clinical trials are needed to establish whether this benefit translates to a longer life. In a heart attack, the blood supply to parts of the heart is cut off by a blocked artery, causing damage to the heart tissue. The cells in the affected area start to die. This is called necrosis and in the days and weeks that follow, the necrotic area may grow, eventually leaving a large part of the heart unable to contract and increasing the risk of further heart problems. Stem cell therapy uses cells from the patient's own bone marrow to try to repair and reduce this damage. Currently, the treatment is only available in facilities with links to scientific research. The authors of the review drew together all the available evidence to ask whether adult bone marrow stem cells can effectively prevent and repair the damage caused by a heart attack. In 2008, a Cochrane review of 13 stem … Continue reading →

Stemedica has been issued U.S. Patent #8,105,380 by the United States Patent and Trademark Office. This broad-based patent covers the combination of scaffolds with stem cells derived from ectodermal and mesenchymal tissue. These multi-stem cell products address need in the $12.5 billion wound care field. San Diego, CA (PRWEB) February 15, 2012 Stemedica Cell Technologies, Inc. (Stemedica), a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued U.S. Patent #8,105,380 by the United States Patent and Trademark Office. This broad-based patent covers the combination of scaffolds with stem cells derived from ectodermal and mesenchymal tissue. Unique features of the invention include a two-layer approach to wound healing: 1) a biodegradable layer that enhances growth factor and cytokine delivery in the wound bed and 2) a non-absorbable biological bandage layer that encourages epidermal closure. Mimicking human skin in its design, the Stemedica product will serve as a skin substitute for full thickness burns and chronic wounds. Estimated sales of wound care products in 2012 are $12.5 Billion. Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica noted, “This patent brings together many aspects of regenerative medicine that are unique to … Continue reading →